Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Fbio save search
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Published: 2024-03-18 (Crawled : 12:30) - globenewswire.com
DERM | $3.52 -0.57% 43K
|
|
| O: 2.94%
H: 14.57%
C: 6.86%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 3.36%
H: 0.5%
C: -4.0%
dfd-29 fda drug corporation treatment medical application
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Published: 2024-01-02 (Crawled : 13:30) - globenewswire.com
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: -0.33%
H: 2.33%
C: -10.33%
ATXI | $0.0945 -29.48% 7.9M
|
Health Technology
|
| O: 8.7%
H: 0.0%
C: -8.57%
aj201 treatment trial therapeutics
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 0.75%
H: 7.43%
C: 4.09%
cutx-101 candidate disease biotech transfer treatment
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
Published: 2023-12-06 (Crawled : 13:30) - globenewswire.com
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 0.75%
H: 7.43%
C: 4.09%
cutx-101 candidate biotech transfer treatment lifesciences
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
MBIO | $0.35 -2.7% 61K
|
Health Technology
|
| O: 10.19%
H: 21.97%
C: -18.5%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: -0.53%
H: 2.93%
C: -4.26%
mb-109 fda mb-101 cell treatment application car-t glioblastoma
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
Published: 2023-10-16 (Crawled : 13:00) - globenewswire.com
AZNCF | News | $140.3 1.5K
|
Health Technology
|
| O: -4.43%
H: 3.6%
C: 3.6%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 0.34%
H: 4.12%
C: -4.81%
AZN | News | $71.065 0.3% 3.2M
|
Health Technology
|
| O: -1.07%
H: 2.0%
C: 1.82%
biotech worldwide hope cell treatment city agreement therapy living
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)Topline data expected in 2024
Published: 2023-07-27 (Crawled : 13:00) - biospace.com/
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 2.6%
H: 0.37%
C: -4.38%
ATXI | $0.0945 -29.48% 7.9M
|
Health Technology
|
| O: 3.7%
H: 1.79%
C: -6.25%
aj201 expected treatment trial therapeutics
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Published: 2023-07-27 (Crawled : 12:20) - globenewswire.com
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 2.6%
H: 0.37%
C: -4.38%
ATXI | $0.0945 -29.48% 7.9M
|
Health Technology
|
| O: 3.7%
H: 1.79%
C: -6.25%
aj201 treatment trial therapeutics
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
DERM | $3.52 -0.57% 43K
|
|
| O: 0.35%
H: 4.91%
C: -17.19%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: -0.61%
H: 3.47%
C: -1.77%
dfd-29 corporation positive treatment trials topline medical results
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023
Published: 2023-07-03 (Crawled : 12:00) - globenewswire.com
DERM | $3.52 -0.57% 43K
|
|
| O: 9.43%
H: 16.67%
C: 14.94%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 1.82%
H: 4.02%
C: 1.29%
dfd-29 corporation treatment trials topline medical week results
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
Published: 2023-03-16 (Crawled : 13:00) - globenewswire.com
DERM | $3.52 -0.57% 43K
|
|
| O: -4.96%
H: 15.3%
C: 10.07%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 2.54%
H: 0.0%
C: 0.0%
dfd-29 corporation treatment impact medical trial phase 1
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
Published: 2023-03-02 (Crawled : 13:20) - globenewswire.com
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ATXI | $0.0945 -29.48% 7.9M
|
Health Technology
|
| O: 13.39%
H: 1.57%
C: -10.24%
aj201 treatment license therapeutics agreement muscular atrophy kennedy’s disease
Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular RosaceaTopline data expected in the first half of 2023
Published: 2023-01-10 (Crawled : 15:00) - biospace.com/
DERM | $3.52 -0.57% 43K
|
|
| O: 3.75%
H: 16.87%
C: 11.45%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 2.49%
H: 1.21%
C: -4.88%
dfd-29 treatment trials medical expected corporation
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Published: 2023-01-04 (Crawled : 13:20) - globenewswire.com
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 6.15%
H: 2.9%
C: 1.45%
CKPT | $1.46 1.74% 87K
|
Health Technology
|
| O: 3.75%
H: 15.7%
C: 4.55%
treatment fda application license therapeutics cell carcinoma cosibelimab
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
Published: 2022-11-08 (Crawled : 14:20) - biospace.com/
AZNCF | News | $140.3 1.5K
|
Health Technology
|
| O: 2.49%
H: 0.0%
C: -1.6%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 0.0%
H: 4.76%
C: -4.6%
ATXI | $0.0945 -29.48% 7.9M
|
Health Technology
|
| O: 7.78%
H: 6.67%
C: -7.78%
AZN | News | $71.065 0.3% 3.2M
|
Health Technology
|
| O: 0.2%
H: 0.96%
C: 0.18%
treatment acquisition system therapeutics positive
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
Published: 2022-05-19 (Crawled : 13:00) - globenewswire.com
MBIO | $0.35 -2.7% 61K
|
Health Technology
|
| O: -2.74%
H: 2.9%
C: -0.53%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: -2.64%
H: 11.49%
C: 5.69%
mb-107 treatment trial therapy phase 2
Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma
Published: 2022-04-13 (Crawled : 15:20) - biospace.com/
MBIO | $0.35 -2.7% 61K
|
Health Technology
|
| O: -1.1%
H: 14.29%
C: -0.99%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: -0.87%
H: 1.75%
C: 0.88%
mb-101 treatment trial phase 1 glioblastoma
Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea
Published: 2022-03-17 (Crawled : 19:00) - biospace.com/
DERM | $3.52 -0.57% 43K
|
|
| O: 1.76%
H: 4.32%
C: -2.81%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 0.77%
H: 8.78%
C: 8.4%
dfd-29 treatment rosa trial corporation phase 3
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
Published: 2022-01-24 (Crawled : 00:00) - biospace.com/
MBIO | $0.35 -2.7% 61K
|
Health Technology
|
| O: -5.38%
H: 5.69%
C: 5.69%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: -1.02%
H: 7.93%
C: 6.95%
mb-207 treatment application gene therapy therapy
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Published: 2021-12-09 (Crawled : 14:00) - globenewswire.com
MBIO | $0.35 -2.7% 61K
|
Health Technology
|
| O: 2.88%
H: 1.87%
C: -3.27%
FBIO | $1.785 -1.38% 69K
|
Health Technology
|
| O: 4.85%
H: 0.0%
C: 0.0%
mb-106 treatment leukemia potential lymphomas t-cell
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.05 44.75% 13M
|
Technology Services
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.